Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 14/20 | 0.69 |
| ▸ | RAB9A | P51151 | 4/20 | 0.69 |
| ▸ | NPC1 | O15118 | 4/20 | 0.69 |
| ▸ | TP53 | P04637 | 3/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.63 |
| ▸ | LMNA | P02545 | 4/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3069004 | 0.79 | NPC1 (0.66) | MAPTRAB9ANPC1TP53ALDH1A1 | |
| SCHEMBL3075247 | 0.75 | MAPT (0.77) | MAPTRAB9ANPC1TP53ALDH1A1 | |
| SCHEMBL18711482 | 0.75 | NPC1 (0.74) | MAPTRAB9ANPC1TP53ALDH1A1 | |
| SCHEMBL13851537 | 0.75 | NPC1 (0.50) | MAPTRAB9ANPC1TP53ALDH1A1 | |
| SCHEMBL8526236 | 0.74 | RAB9A (0.73) | MAPTRAB9ANPC1TP53ALDH1A1 | |
| SCHEMBL3575472 | 0.74 | NPC1 (0.64) | MAPTRAB9ANPC1TP53ALDH1A1 | |
| SCHEMBL11165376 | 0.73 | ALDH1A1 (0.69) | MAPTRAB9ANPC1TP53ALDH1A1 | |
| SCHEMBL11783793 | 0.72 | RAB9A (0.71) | MAPTRAB9ANPC1TP53ALDH1A1 | |
| SCHEMBL7217567 | 0.72 | RAB9A (0.71) | MAPTRAB9ANPC1TP53ALDH1A1 | |
| SCHEMBL20964558 | 0.72 | NPC1 (0.73) | MAPTRAB9ANPC1TP53ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8710088-B2 | Pharmaceutical and diagnostic compositions for use in the treatment and diagnosis of neurodegenerative diseases or amyloid diseases | MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) | 2014-04-29 | — | — | US | disclosed |
| US-8710088-B2 | Pharmaceutical and diagnostic compositions for use in the treatment and diagnosis of neurodegenerative diseases or amyloid diseases | MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) | 2014-04-29 | — | — | US | disclosed |
| US-8710088-B2 | Pharmaceutical and diagnostic compositions for use in the treatment and diagnosis of neurodegenerative diseases or amyloid diseases | MAX-DELBRUCK-CENTRUM FUR MOLEKULARE MEDIZIN (DE) | 2014-04-29 | — | — | US | disclosed |
| US-20090117040-A1 | Novel pharmaceutical and diagnostic compositions for use in the treatment and diagnosis of neurodegenerative diseases or amyloid diseases | MAX-DELBRUG-CENTRUM FUR MOLEKULARE MEDIZIN (DE) | 2009-05-07 | — | — | US | disclosed |
| EP-1713457-A2 | NOVEL DRUGS AND DIAGNOSTIC COMPOSITIONS FOR USE IN THE TREATMENT AND DIAGNOSIS OF NEURODEGENERATIVE DISEASES OR AMYLOID DISEASES | MAX-DELBRÜCK-CENTRUM FÜR MOLEKULARE MEDIZIN (DE) | 2006-10-25 | — | — | EP | disclosed |
| WO-2005077343-A9 | NOVEL DRUGS AND DIAGNOSTIC COMPOSITIONS FOR USE IN THE TREATMENT AND DIAGNOSIS OF NEURODEGENERATIVE DISEASES OR AMYLOID DISEASES | MAX DELBRUECK CENTRUM (DE) | 2005-11-24 | — | — | WO | disclosed |
| WO-2005077343-A2 | NOVEL DRUGS AND DIAGNOSTIC COMPOSITIONS FOR USE IN THE TREATMENT AND DIAGNOSIS OF NEURODEGENERATIVE DISEASES OR AMYLOID DISEASES | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2005-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090117040-A1 | Novel pharmaceutical and diagnostic compositions for use in the treatment and diagnosis of neurodegenerative diseases or amyloid diseases | APP, PSEN2, PSEN1 | MAPT 10/4885RAB9A 2510/4885NPC1 200/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.